DECIPHERA PHARMACEUTICALS IN's ticker is DCPH and the CUSIP is 24344T101. A total of 151 filers reported holding DECIPHERA PHARMACEUTICALS IN in Q1 2020. The put-call ratio across all filers is 0.55 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $635,426 | -95.9% | 18,700 | -94.6% | 0.04% | -96.2% |
| Q1 2021 | $15,501,950 | +10.3% | 345,717 | +40.4% | 1.16% | -29.3% |
| Q4 2020 | $14,052,917 | -31.9% | 246,240 | -38.8% | 1.65% | -64.1% |
| Q3 2020 | $20,644,813 | -17.4% | 402,433 | -3.9% | 4.59% | +33.8% |
| Q2 2020 | $25,001,897 | +46.7% | 418,652 | +1.1% | 3.43% | -19.1% |
| Q1 2020 | $17,047,715 | +112.7% | 414,081 | +221.6% | 4.24% | +199.5% |
| Q4 2019 | $8,013,276 | +973.2% | 128,748 | +485.2% | 1.42% | +509.9% |
| Q3 2019 | $746,680 | -89.2% | 22,000 | -92.8% | 0.23% | -88.0% |
| Q2 2019 | $6,883,004 | +18.4% | 305,233 | +21.9% | 1.93% | +13.6% |
| Q1 2019 | $5,812,527 | +297.3% | 250,432 | +259.3% | 1.70% | +114.1% |
| Q4 2018 | $1,463,003 | +289.9% | 69,700 | +630.9% | 0.79% | +360.5% |
| Q2 2018 | $375,242 | -78.0% | 9,536 | -88.8% | 0.17% | -78.3% |
| Q1 2018 | $1,705,204 | – | 85,090 | – | 0.79% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| New Leaf Venture Partners, L.L.C. | 2,086,723 | $85,910,000 | 25.70% |
| SV Health Investors, LLC | 449,951 | $18,525,000 | 15.54% |
| Redmile Group, LLC | 5,116,263 | $210,637,000 | 5.90% |
| Eversept Partners, LP | 414,081 | $17,047,715 | 4.24% |
| Sunesis Advisors, LLC | 96,299 | $3,965,000 | 3.99% |
| Avoro Capital Advisors LLC | 2,000,000 | $82,340,000 | 2.78% |
| Opaleye Management Inc. | 222,000 | $9,140,000 | 2.42% |
| SECTORAL ASSET MANAGEMENT INC | 204,059 | $8,401,000 | 1.61% |
| Artal Group S.A. | 800,000 | $32,936,000 | 1.39% |
| Atika Capital Management LLC | 141,000 | $5,805,000 | 1.11% |